This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sell, S. Search for Related Content PubMed PubMed Citation Articles by Sell, S. Related Collections Tumor Biology Tumor Biology: Model Organisms and Imaging

Mouse Models to Study the Interaction of Risk Factors for Human Liver Cancer

Ordway Research Institute and Wadsworth Center, Albany, New York

Each of the risk factors for human liver cancer (aflatoxin exposure, hepatitis B virus-associated liver injury, p53 loss, p53ser249 mutation, and male sex) also increases the incidence of hepatocellular carcinoma (HCC) in mouse models of hepatocarcinogenesis. Neonatal mice, partially hepatectomized adult mice, and p53-deficient mice each have a higher hepatocyte proliferation rate, are less able to detoxify AFB1, and form more DNA adducts than do normal wild-type controls. However, transgenic hepatitis B surface antigen mice, expressing hepatitis B surface antigen under control of the albumin promoter (alb/psx), are able to detoxify AFB1 at the same level as do wild-type mice. Thus, AFB1-induced HCC development in neonatal mice and p53+/- mice may be due to "immature" carcinogen metabolism, whereas increased HCC in transgenic hepatitis B virus mice may be due to promotion effects of increased proliferation. Future studies will explore the effects of modifying factors on the development of HCC.

This article has been cited by other articles:

				J. M. Cullen, D. L. Brown, G. E. Kissling, J. F. Foley, J. Rizzo, P. L. Marion, V. I. Parron, and J. E. French Aflatoxin B1 and/or Hepatitis B Virus Induced Tumor Spectrum in a Genetically Engineered Hepatitis B Virus Expression and Trp53 Haploinsufficient Mouse Model System for Hepatocarcinogenesis Toxicol Pathol, April 1, 2009; 37(3): 333 - 342. [Abstract] [Full Text] [PDF]

				G. D. Kirk, E. Bah, and R. Montesano Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa Carcinogenesis, October 1, 2006; 27(10): 2070 - 2082. [Abstract] [Full Text] [PDF]

				D. R. Crawford, S. Ostrowski, D. Vakharia, Z. Ilic, and S. Sell Separate Origins of Hepatitis B Virus Surface Antigen-Negative Foci and Hepatocellular Carcinomas in Transgenic HBsAg (alb/psx) Mice Am. J. Pathol., July 1, 2006; 169(1): 223 - 232. [Abstract] [Full Text] [PDF]

				L. Varghese, C. Agarwal, A. Tyagi, R. P. Singh, and R. Agarwal Silibinin Efficacy against Human Hepatocellular Carcinoma Clin. Cancer Res., December 1, 2005; 11(23): 8441 - 8448. [Abstract] [Full Text] [PDF]